Corporate Update – Q2 2026
Adherium Limited, the Australian medical‑technology company, has reported sustained growth in its remote patient monitoring (RPM) business for the quarter ended 30 June 2026. The company’s recurring subscription revenue from RPM devices rose to record levels, driven by a sharp increase in device shipments and patient activations. In particular, the expansion of its Hailie® sensor platform was highlighted. Clinical validation presented at the American Thoracic Society conference demonstrated significant reductions in health‑care utilisation and marked improvements in patient adherence and retention.
Commercial Strategy and Partnerships
Adherium has integrated its RPM technology into the electronic health‑record (EHR) system of Allergy Partners, a prominent U.S. allergy practice. More than 1,500 patients have already been enrolled, and the partnership is projected to generate additional recurring revenue as more clinic sites activate the platform. The company is also advancing outreach to pulmonology practices, adding 15,000 new patients to its pipeline through targeted engagement. These efforts underscore the firm’s strategy of embedding RPM solutions within established clinical workflows to increase adoption and capture long‑term value.
Leadership Appointment
John Perry has been appointed Chief Commercial Officer to guide the transition toward value‑based care contracts. Perry brings a robust background in commercial growth at large U.S. health‑systems and health‑insurance partners. His experience positions Adherium to leverage its longitudinal patient data for outcome‑based agreements, an essential capability in the evolving U.S. health‑care market that increasingly rewards demonstrable patient outcomes over volume.
Financial Performance
Operating cash outflows declined, with cash and cash equivalents falling to approximately $1.38 million. Net cash used in operating activities was negative, largely attributable to higher staffing and manufacturing costs. Financing activity, however, provided a net inflow of around $2.37 million, driven by new borrowing and equity issuances. The company’s capital structure remains manageable, featuring a modest debt level and a small, unused credit facility. These dynamics illustrate Adherium’s disciplined approach to financing growth while maintaining liquidity.
Strategic Outlook
The update reinforces Adherium’s focus on scaling its RPM platform, deepening clinical partnerships, and building a data foundation that supports value‑based care models in the U.S. market. By aligning technology deployment with clinical needs and contractual incentives, the company is positioning itself to capture market share in an environment where digital health solutions are increasingly integrated into mainstream care delivery.
